Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGOMUNE: regorafenib plus avelumab in advanced solid tumors
2023-509500-15-00Phase 2Authorised
- Sponsor
- Institut Bergonié
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab and regorafenib in Nonhematologic neoplasms, colorectal cancer (CRC), gastrointestinal stromal tumor (GIST) and 15 more (20 arms), sponsored by Institut Bergonié. Primary endpoints: Phase I toxicity, Phase I dose-limiting toxicity incidence and 7 more. Planned start Nov 2024; status: authorised.
02
Drugs
avelumabregorafenib
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)gastrointestinal stromal tumor (GIST)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on 2023-509500-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509500-15-00.